화일약품

061250KOSDAQ의약품 제조업

59.3 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40

News Sentiment16.3 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 6.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hwa-il Pharm Co., Ltd. is a company engaged in the production and sale of pharmaceutical raw materials, finished pharmaceuticals, and functional health food ingredients, with three domestic production facilities and an expansion plan for the Pyeongtaek plant. The business is accelerating growth due to the expansion of the generic drug market and increased demand for antibiotics, with sales reaching 100.8 billion KRW in 2025.

Number of Employees

145people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

0.31Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE

-0.11Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

0.13Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼232.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Negative
'중대산업재해' 화일약품. 前 대표이사 1심 유죄
화일약품의 전 대표이사 유죄 판결로 인해 기업 이미지와 신뢰도 하락 예상.

Detailed Momentum

52-week position8.0Point

Near 52w high (81%, uptrend)

Current 7,510Won52-week high 9,03052-week low 918

1-month return2.0Point

1m -6.82% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-09
Neutral중대재해관련형사처벌사실확인2026-05-29
Neutral분기보고서 (2026.03)2026-05-15